Sleep Review
  • Disorders
    • Breathing Disorders
    • Insomnia
    • Hypersomnias
    • Movement Disorders
    • Circadian Rhythm Disorders
    • Parasomnias
  • Diagnostics
    • Screeners
    • In-Lab Tests
    • Home Based/Out of Lab
    • Connected Care
    • Consumer Sleep Tracking
  • Treatments
    • Therapy Devices
    • Pharmaceuticals
    • Surgeries & Procedures
    • Behavioral Sleep Medicine
  • Health
    • Parameters
    • Demographics
    • Sleep & Body Systems
    • Prevailing Attitudes
  • Practice Management
    • Money
    • Laws & Regulations
    • Marketing
    • Human Resources
  • Earn CEC
  • Resources
    • Podcasts
    • Webinars
    • White Papers
    • Videos
  • Digital Edition

Select Page

Tag: KemPharm

All

Latest
Zevra’s Leading Drug Candidate for Idiopathic Hypersomnia Treatment Advancing

Zevra’s Leading Drug Candidate for Idiopathic Hypersomnia Treatment Advancing

The company also announced plans to begin a search for a new CEO to succeed Richard W. Pascoe, who will retire on June 1.

  • KemPharm Rebrands as Zevra Therapeutics

  • KemPharm, Hypersomnia Foundation Partner to Support Sleep Disorder Research & Advocacy

  • KemPharm Starts Phase 2 Trial Investigating KP1077 for Idiopathic Hypersomnia

  • KemPharm Gets FDA Orphan Drug Designation for Serdexmethylphenidate for Idiopathic Hypersomnia

  • New Idiopathic Hypersomnia Drug Candidate Set to Enter Clinical Trials Later This Year

All

Latest
Sorry, No Posts Found

All

Latest
Sorry, No Posts Found
Sorry, No Posts Found

Sleep Review

7300 W 110th St – Floor 7
Overland Park, KS 66210

Our Parent Company

MEDQOR LLC

About MEDQOR

MEDQOR Data Platform

Media Solutions Kit

Press Releases

Key Resources

Digital Edition

Podcasts

Webinars

White Papers

Videos

Helpful Links

Submit a Press Release

Advisory Board

Submit an Article

Subscribe

Contact Us

  • Follow
  • Follow
  • Follow
  • Follow

Copyright

Privacy Policy

Terms of Service

© 2026 MEDQOR LLC. All Rights Reserved

✖